Series Unknown Funded Biotechnology Research Startups
The 10 most recent Series Unknown rounds in biotechnology research span April 2022 through April 2025, with disclosed amounts ranging from $50K (Walela, Ch…
The 10 most recent Series Unknown rounds in biotechnology research span April 2022 through April 2025, with disclosed amounts ranging from $50K (Walela, Chicago) to $18M (Rebus Biosystems, Santa Clara). HAON Life Sciences in Dublin closed the most recent entry at $12M in April 2025, while four separate rounds — Love Lifesciences, Cybele Microbiome, The Citizen Science Lab, and Rebus Biosystems — all closed in November 2022, the densest cluster in the dataset. TeraCyte Analytics (Caesarea, Israel) is the only company that closed on fully undisclosed terms.
Eight of the 10 companies are US-based, with California represented twice and the Midwest appearing across Cincinnati, Overland Park, Pittsburgh, and Chicago. International presence is limited to Dublin and Caesarea. Round sizes are broadly dispersed — six of nine disclosed figures sit at or below $5M — consistent with the heterogeneous nature of the Series Unknown label, which captures early-stage checks, bridge structures, and rounds where classification was not reported.
Most recent rounds
10 shownRelated listings
Frequently asked
What are the largest disclosed rounds among these companies?
Rebus Biosystems (Santa Clara, California) raised the largest amount at $18M in November 2022, followed by HAON Life Sciences (Dublin, Ireland) at $12M in April 2025. The majority of other disclosed rounds in the dataset sit at or below $5M, with Walela (Chicago) at the low end at $50K.
How geographically distributed are these biotechnology research companies?
Eight of the 10 companies are US-based, spanning California (Rebus Biosystems in Santa Clara, Cybele Microbiome in San Diego), Texas (FibroBiologics in Houston), Ohio (Orange Grove Bio in Cincinnati), Kansas, Pennsylvania, Illinois, and a location listed as Canada, Kentucky. The two non-US companies are HAON Life Sciences in Dublin, Ireland, and TeraCyte Analytics in Caesarea, Israel.
Is there any company in this segment with an undisclosed round size?
TeraCyte Analytics, based in Caesarea, Israel, closed a Series Unknown round in June 2023 on undisclosed terms. All other nine companies in the dataset have reported figures ranging from $50K to $18M.
Was there a notable period of concentrated funding activity in this segment?
Four of the 10 rounds closed within a single month — November 2022 — covering Love Lifesciences (Overland Park), Cybele Microbiome (San Diego), The Citizen Science Lab (Pittsburgh), and Rebus Biosystems (Santa Clara). The most recent entry, HAON Life Sciences, closed in April 2025, roughly two and a half years later.
What does the typical deal size look like for Series Unknown biotechnology research rounds?
Among the nine companies with disclosed amounts, six raised $5M or less. The range is wide — from $50K (Walela, Chicago) to $18M (Rebus Biosystems, Santa Clara) — reflecting the heterogeneous nature of the Series Unknown classification, which can include early pre-seed checks, undisclosed bridge rounds, and grant-adjacent capital.
Are there any non-US hubs appearing in this segment?
Dublin, Ireland appears via HAON Life Sciences ($12M, April 2025), and Caesarea in Israel's Haifa district appears via TeraCyte Analytics (undisclosed, June 2023). The Verschuren Centre is listed with a Canadian association despite a US address, suggesting cross-border research affiliations are present in the segment.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.